AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation

Xin Wu, Yuanhuan Yu, Meiyan Wang, Di Dai, Jianli Yin, Wenjing Liu, Deqiang Kong, Shasha Tang, Meiyao Meng, Tian Gao, Yuanjin Zhang, Yang Zhou, Ningzi Guan, Shangang Zhao, Haifeng Ye

Research output: Contribution to journalArticlepeer-review


Gene therapies provide treatment options for many diseases, but the safe and long-term control of therapeutic transgene expression remains a primary issue for clinical applications. Here, we develop a muscone-induced transgene system packaged into adeno-associated virus (AAV) vectors (AAVMUSE) based on a G protein-coupled murine olfactory receptor (MOR215-1) and a synthetic cAMP-responsive promoter (PCRE). Upon exposure to the trigger, muscone binds to MOR215-1 and activates the cAMP signaling pathway to initiate transgene expression. AAVMUSE enables remote, muscone dose- and exposure-time-dependent control of luciferase expression in the livers or lungs of mice for at least 20 weeks. Moreover, we apply this AAVMUSE to treat two chronic inflammatory diseases: nonalcoholic fatty liver disease (NAFLD) and allergic asthma, showing that inhalation of muscone—after only one injection of AAVMUSE—can achieve long-term controllable expression of therapeutic proteins (ΔhFGF21 or ΔmIL-4). Our odorant-molecule-controlled system can advance gene-based precision therapies for human diseases.

Original languageEnglish (US)
JournalNature communications
Issue number1
StatePublished - Dec 2024

ASJC Scopus subject areas

  • General Chemistry
  • General Biochemistry, Genetics and Molecular Biology
  • General Physics and Astronomy


Dive into the research topics of 'AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation'. Together they form a unique fingerprint.

Cite this